
Affimed N.V. AFMD
Quarterly report 2022-Q2
added 08-11-2022
Affimed N.V. Operating Cash Flow 2011-2026 | AFMD
Annual Operating Cash Flow Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 M | -19.4 M | -29.1 M | 49.4 M | -25.5 M | -32.1 M | -18.5 M | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.4 M | -86.6 M | -23.1 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
argenx SE
ARGX
|
-607 M | $ 831.0 | -0.3 % | $ 25 B | ||
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
6.88 M | $ 14.75 | -0.74 % | $ 6.01 B | ||
|
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-39 M | $ 4.12 | 5.07 % | $ 351 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
Adagene
ADAG
|
-29.7 M | $ 3.17 | 11.23 % | $ 178 M | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
Aptorum Group Limited
APM
|
-1.19 M | $ 0.77 | -10.2 % | $ 4.2 M | ||
|
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.48 | -0.83 % | $ 8.37 B | ||
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
-418 M | $ 215.19 | -1.33 % | $ 5 B | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | ||
|
Biogen
BIIB
|
2.2 B | $ 197.11 | 0.82 % | $ 28.9 B | ||
|
Aridis Pharmaceuticals
ARDS
|
-29.1 M | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | ||
|
Bristol-Myers Squibb Company
BMY
|
14.2 B | $ 60.64 | 1.33 % | $ 123 B | ||
|
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | ||
|
BioNTech SE
BNTX
|
890 M | $ 106.73 | 0.92 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B | ||
|
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.4 | 1.59 % | $ 357 M | ||
|
Burford Capital Limited
BUR
|
181 M | $ 9.35 | 0.54 % | $ 1.51 B | ||
|
Amneal Pharmaceuticals
AMRX
|
295 M | $ 14.93 | 2.05 % | $ 4.61 B | ||
|
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B |